{"success":true,"data":{"pressRelease":{"id":"35518","rtpr_id":"nGNE81Njrt","ticker":"NCNA","exchange":"NASDAQ","all_tickers":["NCNA"],"title":"NuCana Reports First Quarter 2026 Financial Results and Provides Business Update","author":"Globe Newswire","published_at":"2026-05-14T20:01:00.449Z","article_body":"Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026\n\nNUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on\nMelanoma\n\nAdvancing Additional Indications and Combination Strategies\n\nCash Runway Expected to Extend into 2029\n\nEDINBURGH, United Kingdom, May 14, 2026 (GLOBE NEWSWIRE) -- NuCana plc\n(NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial\nresults for the first quarter ended March 31, 2026 and provided an update on\nits clinical development program with its two lead anti-cancer medicines.\n\n\"We are pleased to report continued progress in the first quarter of 2026 as\nNUC-7738 advances towards important clinical and regulatory milestones,\" said\nHugh S. Griffith, NuCana's Founder and Chief Executive Officer. \"During the\nquarter, we continued to advance enrollment for our Phase 2 NuTide:701\nexpansion study evaluating NUC-7738 in combination with Keytruda®\n(pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma.\nThe clinical activity and favorable safety profile previously reported,\nincluding confirmed objective responses and prolonged disease control,\ncontinue to support the therapeutic potential of NUC-7738 in this patient\npopulation, and we look forward to reporting final data from this study, which\nis expected later in 2026.\"\n\n\"We are also delighted to announce that the U.S. Food and Drug Administration\n(the “FDA”) cleared our Investigational New Drug application (“IND”)\nfor NUC-7738 in April 2026. This important milestone enables clinical\ninvestigation of NUC-7738 in the United States and we expect our initial focus\nwill be in patients with melanoma. We look forward to advancing our dialogue\nwith the FDA to determine the optimal pathway toward a potential\nregistrational strategy for NUC-7738 in melanoma.\"\n\nMr. Griffith continued, \"Beyond our near-term, anticipated milestones in\nmelanoma, we are actively exploring opportunities to broaden the clinical\nutility of NUC-7738 through additional indications and combination strategies.\nThe mechanism of action of NUC-7738, disrupting RNA polyadenylation and\ntargeting multiple aspects of the tumor microenvironment, positions it as a\npotentially versatile agent across a range of tumor types, and we are\nencouraged by the scientific rationale supporting its evaluation in new\nsettings. We believe these efforts have the potential to significantly expand\nthe long-term value of NUC-7738 for patients and for NuCana.\"\n\nMr. Griffith concluded, \"Our strong balance sheet, with cash resources\nexpected to fund operations into 2029, provides us with the financial\nflexibility to execute on our strategic priorities and advance our pipeline.\nWe look forward to achieving important anticipated milestones throughout the\nremainder of 2026.\"\n\n2026 Anticipated Milestones\n* NUC-7738 * Complete patient recruitment in the Phase 2 expansion study\n(NuTide:701) evaluating NUC-7738 in combination with pembrolizumab in patients\nwith PD-1 inhibitor-resistant melanoma;\n* Announce final data from the Phase 2 expansion study (NuTide:701) of\nNUC-7738 in combination with pembrolizumab in patients with PD-1\ninhibitor-resistant melanoma;\n* Obtain regulatory guidance from the FDA regarding a potential registrational\nstrategy for NUC-7738 in melanoma; and\n* Advance evaluation of additional indications and combination strategies.\n \n* NUC-3373 * Complete evaluation of optimal combinations and indications to\ninform potential future clinical studies of NUC-3373.\nFirst Quarter 2026 Financial Highlights and Cash Position\n\nAs at March 31, 2026, NuCana had cash and cash equivalents of £21.5 million\ncompared to £24.3 million at December 31, 2025. NuCana anticipates its cash\nand cash equivalents at March 31, 2026 will be sufficient to fund its planned\noperations into 2029.\n\nNuCana reported a net loss of £3.9 million for the quarter ended March 31,\n2026, as compared to a net loss of £2.5 million for the quarter ended March\n31, 2025. The net loss for the quarter ended March 31, 2026 included non-cash\nshare-based payment expenses of £1.9 million (2025: £0.3 million).\n\nBasic and diluted loss per ordinary share was £0.00 for the quarter ended\nMarch 31, 2026, as compared to a loss per ordinary share of £0.02 for the\ncomparable quarter ended March 31, 2025.\n\nAbout NuCana\n\nNuCana is a clinical-stage biopharmaceutical company focused on significantly\nimproving treatment outcomes for patients with cancer by applying our ProTide\ntechnology to transform some of the most widely prescribed chemotherapy\nagents, nucleoside analogs, into more effective and safer medicines. While\nthese conventional agents remain part of the standard of care for the\ntreatment of many solid and hematological tumors, they have significant\nshortcomings that limit their efficacy and they are often poorly tolerated.\nUtilizing our proprietary technology, we are developing new medicines,\nProTides, designed to overcome the key limitations of nucleoside analogs and\ngenerate much higher concentrations of anti-cancer metabolites in cancer\ncells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel\nanti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene\nexpression in cancer cells and targets multiple aspects of the tumor\nmicroenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which\nis evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors\nand in combination with pembrolizumab in patients with melanoma. NUC-3373 is a\ntargeted thymidylate synthase (“TS”) inhibitor designed to overcome key\npharmacological limitations associated with other TS inhibitors. NUC-3373 has\nrecently been evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373\nin combination with the PD-1 inhibitor pembrolizumab for patients with\nadvanced solid tumors and in combination with docetaxel for patients with lung\ncancer, and NuCana is currently evaluating further characterization of mode of\naction and target indications for further clinical studies of NUC-3373.\n\nForward-Looking Statements\nThis press release may contain “forward-looking” statements within the\nmeaning of the Private Securities Litigation Reform Act of 1995 that are based\non the beliefs and assumptions and on information currently available to\nmanagement of the Company. All statements other than statements of historical\nfact contained in this press release are forward-looking statements, including\nstatements concerning the Company’s planned and ongoing clinical studies for\nthe Company’s product candidates and the potential advantages of those\nproduct candidates, including NUC-7738 and NUC-3373; the initiation,\nenrollment, timing, progress, release of data from and results of those\nplanned and ongoing clinical studies; the Company’s goals with respect to\nthe development, regulatory pathway and potential use, if approved, of each of\nits product candidates; the utility of prior non-clinical and clinical data in\ndetermining future clinical results; and the sufficiency of the Company’s\ncurrent cash and cash equivalents to fund its planned operations into 2029. In\nsome cases, you can identify forward-looking statements by terminology such as\n“may,” “will,” “should,” “expects,” “plans,”\n“anticipates,” “believes,” “estimates,” “predicts,”\n“potential” or “continue” or the negative of these terms or other\ncomparable terminology. Forward-looking statements involve known and unknown\nrisks, uncertainties and other factors that may cause the Company’s actual\nresults, performance or achievements to be materially different from any\nfuture results, performance or achievements expressed or implied by the\nforward-looking statements. These risks and uncertainties include, but are not\nlimited to, our ability to raise additional capital sufficient to fund our\nplanned operations and the risks and uncertainties set forth in the “Risk\nFactors” section of the Company’s Annual Report on Form 20-F for the year\nended December 31, 2025 filed with the Securities and Exchange Commission\n(“SEC”) on March 19, 2026, and subsequent reports that the Company files\nwith the SEC. Forward-looking statements represent the Company’s beliefs and\nassumptions only as of the date of this press release. Although the Company\nbelieves that the expectations reflected in the forward-looking statements are\nreasonable, it cannot guarantee future results, levels of activity,\nperformance or achievements. Except as required by law, the Company assumes no\nobligation to publicly update any forward-looking statements for any reason\nafter the date of this press release to conform any of the forward-looking\nstatements to actual results or to changes in its expectations.\n\n \n Unaudited Condensed Consolidated Statements of Operations \n \n For the Three Months Ended March 31, \n 2026 2025 \n (in thousands, except per share data) \n £ £ \n Research and development expenses (3,213 ) (1,725 ) \n Administrative expenses (1,568 ) (1,067 ) \n Net foreign exchange gains (losses) 363 (59 ) \n Operating loss (4,418 ) (2,851 ) \n Finance income 143 25 \n Loss before tax (4,275 ) (2,826 ) \n Income tax credit 410 353 \n Loss for the period attributable to equity holders of the Company (3,865 ) (2,473 ) \n Basic and diluted loss per ordinary share (0.00 ) (0.02 ) \n\n\n\n \n Unaudited Condensed Consolidated Statements of Financial Position As At \n \n March 31, 2026 December 31, 2025 \n (in thousands) \n £ £ \n Assets \n Non-current assets \n Intangible assets 2,224 2,198 \n Property, plant and equipment 641 658 \n Deferred tax asset 122 117 \n 2,987 2,973 \n Current assets \n Prepayments, accrued income and other receivables 869 849 \n Current income tax receivable 2,168 1,761 \n Cash and cash equivalents 21,529 24,251 \n 24,566 26,861 \n Total assets 27,553 29,834 \n Equity and liabilities \n Capital and reserves \n Share capital and share premium 189,586 189,586 \n Other reserves 83,953 87,075 \n Accumulated deficit (251,172 ) (252,334 ) \n Total equity attributable to equity holders of the Company 22,367 24,327 \n Non-current liabilities \n Provisions 58 58 \n Lease liabilities 647 656 \n 705 714 \n Current liabilities \n Trade payables 673 522 \n Payroll taxes and social security 138 99 \n Accrued expenditure 3,637 4,152 \n Lease liabilities 33 20 \n 4,481 4,793 \n Total liabilities 5,186 5,507 \n Total equity and liabilities 27,553 29,834 \n \n\n\n\n \n Unaudited Condensed Consolidated Statements of Cash Flows \n \n For the Three Months Ended March 31, \n 2026 2025 \n (in thousands ) \n £ £ \n Cash flows from operating activities \n Loss for the period (3,865 ) (2,473 ) \n Adjustments for: \n Income tax credit (410 ) (353 ) \n Amortization and depreciation 68 67 \n Finance income (143 ) (25 ) \n Interest expense on lease liabilities 12 3 \n Share-based payments 1,887 258 \n Net foreign exchange (gains) losses (380 ) 101 \n (2,831 ) (2,422 ) \n Movements in working capital: \n Increase in prepayments, accrued income and other receivables (26 ) (309 ) \n Increase (decrease) in trade payables 151 (302 ) \n Decrease in payroll taxes, social security and accrued expenditure (476 ) (1,075 ) \n Movements in working capital (351 ) (1,686 ) \n Cash used in operations (3,182 ) (4,108 ) \n Net income tax received - 999 \n Net cash used in operating activities (3,182 ) (3,109 ) \n Cash flows from investing activities \n Interest received 149 28 \n Payments for intangible assets (77 ) (39 ) \n Net cash from (used in) investing activities 72 (11 ) \n Cash flows from financing activities \n Payments for lease liabilities (7 ) (20 ) \n Proceeds from exercise of share options - 1 \n Proceeds from issue of share capital - 475 \n Share issue expenses - (14 ) \n Net cash (used in) from financing activities (7 ) 442 \n Net decrease in cash and cash equivalents (3,117 ) (2,678 ) \n Cash and cash equivalents at beginning of period 24,251 6,749 \n Effect of exchange rate changes on cash and cash equivalents 395 (118 ) \n Cash and cash equivalents at end of period 21,529 3,953 \n \n\nFor more information, please contact:\n\nNuCana plc\nHugh S. Griffith\nChief Executive Officer\n+44 131-357-1111 \ninfo@nucana.com\n\nICR Healthcare\nChris Brinzey\n+1 339-970-2843\nChris.Brinzey@ICRHealthcare.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE81Njrt","title":"NuCana Reports First Quarter 2026 Financial Results and Provides Business Update","author":"Globe Newswire","ticker":"NCNA","created":"2026-05-14T20:01:00.449Z","tickers":["NCNA"],"exchange":"NASDAQ","article_body":"Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026\n\nNUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on\nMelanoma\n\nAdvancing Additional Indications and Combination Strategies\n\nCash Runway Expected to Extend into 2029\n\nEDINBURGH, United Kingdom, May 14, 2026 (GLOBE NEWSWIRE) -- NuCana plc\n(NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial\nresults for the first quarter ended March 31, 2026 and provided an update on\nits clinical development program with its two lead anti-cancer medicines.\n\n\"We are pleased to report continued progress in the first quarter of 2026 as\nNUC-7738 advances towards important clinical and regulatory milestones,\" said\nHugh S. Griffith, NuCana's Founder and Chief Executive Officer. \"During the\nquarter, we continued to advance enrollment for our Phase 2 NuTide:701\nexpansion study evaluating NUC-7738 in combination with Keytruda®\n(pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma.\nThe clinical activity and favorable safety profile previously reported,\nincluding confirmed objective responses and prolonged disease control,\ncontinue to support the therapeutic potential of NUC-7738 in this patient\npopulation, and we look forward to reporting final data from this study, which\nis expected later in 2026.\"\n\n\"We are also delighted to announce that the U.S. Food and Drug Administration\n(the “FDA”) cleared our Investigational New Drug application (“IND”)\nfor NUC-7738 in April 2026. This important milestone enables clinical\ninvestigation of NUC-7738 in the United States and we expect our initial focus\nwill be in patients with melanoma. We look forward to advancing our dialogue\nwith the FDA to determine the optimal pathway toward a potential\nregistrational strategy for NUC-7738 in melanoma.\"\n\nMr. Griffith continued, \"Beyond our near-term, anticipated milestones in\nmelanoma, we are actively exploring opportunities to broaden the clinical\nutility of NUC-7738 through additional indications and combination strategies.\nThe mechanism of action of NUC-7738, disrupting RNA polyadenylation and\ntargeting multiple aspects of the tumor microenvironment, positions it as a\npotentially versatile agent across a range of tumor types, and we are\nencouraged by the scientific rationale supporting its evaluation in new\nsettings. We believe these efforts have the potential to significantly expand\nthe long-term value of NUC-7738 for patients and for NuCana.\"\n\nMr. Griffith concluded, \"Our strong balance sheet, with cash resources\nexpected to fund operations into 2029, provides us with the financial\nflexibility to execute on our strategic priorities and advance our pipeline.\nWe look forward to achieving important anticipated milestones throughout the\nremainder of 2026.\"\n\n2026 Anticipated Milestones\n* NUC-7738 * Complete patient recruitment in the Phase 2 expansion study\n(NuTide:701) evaluating NUC-7738 in combination with pembrolizumab in patients\nwith PD-1 inhibitor-resistant melanoma;\n* Announce final data from the Phase 2 expansion study (NuTide:701) of\nNUC-7738 in combination with pembrolizumab in patients with PD-1\ninhibitor-resistant melanoma;\n* Obtain regulatory guidance from the FDA regarding a potential registrational\nstrategy for NUC-7738 in melanoma; and\n* Advance evaluation of additional indications and combination strategies.\n \n* NUC-3373 * Complete evaluation of optimal combinations and indications to\ninform potential future clinical studies of NUC-3373.\nFirst Quarter 2026 Financial Highlights and Cash Position\n\nAs at March 31, 2026, NuCana had cash and cash equivalents of £21.5 million\ncompared to £24.3 million at December 31, 2025. NuCana anticipates its cash\nand cash equivalents at March 31, 2026 will be sufficient to fund its planned\noperations into 2029.\n\nNuCana reported a net loss of £3.9 million for the quarter ended March 31,\n2026, as compared to a net loss of £2.5 million for the quarter ended March\n31, 2025. The net loss for the quarter ended March 31, 2026 included non-cash\nshare-based payment expenses of £1.9 million (2025: £0.3 million).\n\nBasic and diluted loss per ordinary share was £0.00 for the quarter ended\nMarch 31, 2026, as compared to a loss per ordinary share of £0.02 for the\ncomparable quarter ended March 31, 2025.\n\nAbout NuCana\n\nNuCana is a clinical-stage biopharmaceutical company focused on significantly\nimproving treatment outcomes for patients with cancer by applying our ProTide\ntechnology to transform some of the most widely prescribed chemotherapy\nagents, nucleoside analogs, into more effective and safer medicines. While\nthese conventional agents remain part of the standard of care for the\ntreatment of many solid and hematological tumors, they have significant\nshortcomings that limit their efficacy and they are often poorly tolerated.\nUtilizing our proprietary technology, we are developing new medicines,\nProTides, designed to overcome the key limitations of nucleoside analogs and\ngenerate much higher concentrations of anti-cancer metabolites in cancer\ncells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel\nanti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene\nexpression in cancer cells and targets multiple aspects of the tumor\nmicroenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which\nis evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors\nand in combination with pembrolizumab in patients with melanoma. NUC-3373 is a\ntargeted thymidylate synthase (“TS”) inhibitor designed to overcome key\npharmacological limitations associated with other TS inhibitors. NUC-3373 has\nrecently been evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373\nin combination with the PD-1 inhibitor pembrolizumab for patients with\nadvanced solid tumors and in combination with docetaxel for patients with lung\ncancer, and NuCana is currently evaluating further characterization of mode of\naction and target indications for further clinical studies of NUC-3373.\n\nForward-Looking Statements\nThis press release may contain “forward-looking” statements within the\nmeaning of the Private Securities Litigation Reform Act of 1995 that are based\non the beliefs and assumptions and on information currently available to\nmanagement of the Company. All statements other than statements of historical\nfact contained in this press release are forward-looking statements, including\nstatements concerning the Company’s planned and ongoing clinical studies for\nthe Company’s product candidates and the potential advantages of those\nproduct candidates, including NUC-7738 and NUC-3373; the initiation,\nenrollment, timing, progress, release of data from and results of those\nplanned and ongoing clinical studies; the Company’s goals with respect to\nthe development, regulatory pathway and potential use, if approved, of each of\nits product candidates; the utility of prior non-clinical and clinical data in\ndetermining future clinical results; and the sufficiency of the Company’s\ncurrent cash and cash equivalents to fund its planned operations into 2029. In\nsome cases, you can identify forward-looking statements by terminology such as\n“may,” “will,” “should,” “expects,” “plans,”\n“anticipates,” “believes,” “estimates,” “predicts,”\n“potential” or “continue” or the negative of these terms or other\ncomparable terminology. Forward-looking statements involve known and unknown\nrisks, uncertainties and other factors that may cause the Company’s actual\nresults, performance or achievements to be materially different from any\nfuture results, performance or achievements expressed or implied by the\nforward-looking statements. These risks and uncertainties include, but are not\nlimited to, our ability to raise additional capital sufficient to fund our\nplanned operations and the risks and uncertainties set forth in the “Risk\nFactors” section of the Company’s Annual Report on Form 20-F for the year\nended December 31, 2025 filed with the Securities and Exchange Commission\n(“SEC”) on March 19, 2026, and subsequent reports that the Company files\nwith the SEC. Forward-looking statements represent the Company’s beliefs and\nassumptions only as of the date of this press release. Although the Company\nbelieves that the expectations reflected in the forward-looking statements are\nreasonable, it cannot guarantee future results, levels of activity,\nperformance or achievements. Except as required by law, the Company assumes no\nobligation to publicly update any forward-looking statements for any reason\nafter the date of this press release to conform any of the forward-looking\nstatements to actual results or to changes in its expectations.\n\n \n Unaudited Condensed Consolidated Statements of Operations \n \n For the Three Months Ended March 31, \n 2026 2025 \n (in thousands, except per share data) \n £ £ \n Research and development expenses (3,213 ) (1,725 ) \n Administrative expenses (1,568 ) (1,067 ) \n Net foreign exchange gains (losses) 363 (59 ) \n Operating loss (4,418 ) (2,851 ) \n Finance income 143 25 \n Loss before tax (4,275 ) (2,826 ) \n Income tax credit 410 353 \n Loss for the period attributable to equity holders of the Company (3,865 ) (2,473 ) \n Basic and diluted loss per ordinary share (0.00 ) (0.02 ) \n\n\n\n \n Unaudited Condensed Consolidated Statements of Financial Position As At \n \n March 31, 2026 December 31, 2025 \n (in thousands) \n £ £ \n Assets \n Non-current assets \n Intangible assets 2,224 2,198 \n Property, plant and equipment 641 658 \n Deferred tax asset 122 117 \n 2,987 2,973 \n Current assets \n Prepayments, accrued income and other receivables 869 849 \n Current income tax receivable 2,168 1,761 \n Cash and cash equivalents 21,529 24,251 \n 24,566 26,861 \n Total assets 27,553 29,834 \n Equity and liabilities \n Capital and reserves \n Share capital and share premium 189,586 189,586 \n Other reserves 83,953 87,075 \n Accumulated deficit (251,172 ) (252,334 ) \n Total equity attributable to equity holders of the Company 22,367 24,327 \n Non-current liabilities \n Provisions 58 58 \n Lease liabilities 647 656 \n 705 714 \n Current liabilities \n Trade payables 673 522 \n Payroll taxes and social security 138 99 \n Accrued expenditure 3,637 4,152 \n Lease liabilities 33 20 \n 4,481 4,793 \n Total liabilities 5,186 5,507 \n Total equity and liabilities 27,553 29,834 \n \n\n\n\n \n Unaudited Condensed Consolidated Statements of Cash Flows \n \n For the Three Months Ended March 31, \n 2026 2025 \n (in thousands ) \n £ £ \n Cash flows from operating activities \n Loss for the period (3,865 ) (2,473 ) \n Adjustments for: \n Income tax credit (410 ) (353 ) \n Amortization and depreciation 68 67 \n Finance income (143 ) (25 ) \n Interest expense on lease liabilities 12 3 \n Share-based payments 1,887 258 \n Net foreign exchange (gains) losses (380 ) 101 \n (2,831 ) (2,422 ) \n Movements in working capital: \n Increase in prepayments, accrued income and other receivables (26 ) (309 ) \n Increase (decrease) in trade payables 151 (302 ) \n Decrease in payroll taxes, social security and accrued expenditure (476 ) (1,075 ) \n Movements in working capital (351 ) (1,686 ) \n Cash used in operations (3,182 ) (4,108 ) \n Net income tax received - 999 \n Net cash used in operating activities (3,182 ) (3,109 ) \n Cash flows from investing activities \n Interest received 149 28 \n Payments for intangible assets (77 ) (39 ) \n Net cash from (used in) investing activities 72 (11 ) \n Cash flows from financing activities \n Payments for lease liabilities (7 ) (20 ) \n Proceeds from exercise of share options - 1 \n Proceeds from issue of share capital - 475 \n Share issue expenses - (14 ) \n Net cash (used in) from financing activities (7 ) 442 \n Net decrease in cash and cash equivalents (3,117 ) (2,678 ) \n Cash and cash equivalents at beginning of period 24,251 6,749 \n Effect of exchange rate changes on cash and cash equivalents 395 (118 ) \n Cash and cash equivalents at end of period 21,529 3,953 \n \n\nFor more information, please contact:\n\nNuCana plc\nHugh S. Griffith\nChief Executive Officer\n+44 131-357-1111 \ninfo@nucana.com\n\nICR Healthcare\nChris Brinzey\n+1 339-970-2843\nChris.Brinzey@ICRHealthcare.com"},"type":"article","timestamp":"2026-05-14T20:01:00.526458475Z","server_sent_at_ms":1778788860526},"received_at":"2026-05-14T20:01:00.667Z","source_url":null},"analysis":{"id":"24962","press_release_id":"35518","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"NuCana reported Q1 2026 results with a net loss of £3.9 million and cash reserves of £21.5 million, sufficient to fund operations into 2029.\n\nThe company highlighted that the FDA cleared its IND for NUC-7738 in April 2026, enabling initial clinical studies in melanoma patients in the United States.\n\nNuCana expects to report final data from its Phase 2 expansion study of NUC-7738 in combination with pembrolizumab later in 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"NuCana secures US IND clearance for lead asset NUC-7738; cash runway extends to 2029."},"keyFigures":{"eps":0,"revenue":0,"customDimensions":{"cash_runway_year":2029,"net_loss_q1_2025_gbp":2473000,"net_loss_q1_2026_gbp":3865000,"rd_expense_q1_2026_gbp":3213000,"cash_and_equivalents_gbp":21529000,"share_based_payments_gbp":1887000,"admin_expense_q1_2026_gbp":1568000}},"quotedText":"We are also delighted to announce that the U.S. Food and Drug Administration (the “FDA”) cleared our Investigational New Drug application (“IND”) for NUC-7738 in April 2026.","namedEntities":{"people":[{"name":"Hugh S. Griffith","role":"Founder and Chief Executive Officer"},{"name":"Chris Brinzey","role":"IR Contact"}],"products":["NUC-7738","NUC-3373","Keytruda","pembrolizumab"],"companies":[{"name":"NuCana plc","ticker":"NCNA","relationship":"filer"},{"name":"FDA","relationship":"regulator"},{"name":"ICR Healthcare","relationship":"IR agency"}],"dollarAmounts":[{"amount":"£21.5 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"£24.3 million","context":"Cash and cash equivalents as of December 31, 2025"},{"amount":"£3.9 million","context":"Net loss for Q1 2026"},{"amount":"£2.5 million","context":"Net loss for Q1 2025"},{"amount":"£1.9 million","context":"Non-cash share-based payment expenses Q1 2026"}]},"materialImpact":{"score":2,"reasoning":"Routine quarterly financial update for a clinical-stage biotech with no revenue. The primary news is the FDA IND clearance for NUC-7738 in the US, which is a positive operational milestone but not a binary approval event. Financials show expected burn with a long cash runway."},"tickerRelevance":{"others":[],"primary":"NCNA"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_earnings_plus_ind_clearance","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"earnings","event_type_secondary":["clinical_trial"],"sentiment":"neutral","material_impact_score":2,"narrative":"NuCana reported Q1 2026 results with a net loss of £3.9 million and cash reserves of £21.5 million, sufficient to fund operations into 2029.\n\nThe company highlighted that the FDA cleared its IND for NUC-7738 in April 2026, enabling initial clinical studies in melanoma patients in the United States.\n\nNuCana expects to report final data from its Phase 2 expansion study of NUC-7738 in combination with pembrolizumab later in 2026.","key_figures":{"eps":0,"revenue":0,"customDimensions":{"cash_runway_year":2029,"net_loss_q1_2025_gbp":2473000,"net_loss_q1_2026_gbp":3865000,"rd_expense_q1_2026_gbp":3213000,"cash_and_equivalents_gbp":21529000,"share_based_payments_gbp":1887000,"admin_expense_q1_2026_gbp":1568000}},"named_entities":{"people":[{"name":"Hugh S. Griffith","role":"Founder and Chief Executive Officer"},{"name":"Chris Brinzey","role":"IR Contact"}],"products":["NUC-7738","NUC-3373","Keytruda","pembrolizumab"],"companies":[{"name":"NuCana plc","ticker":"NCNA","relationship":"filer"},{"name":"FDA","relationship":"regulator"},{"name":"ICR Healthcare","relationship":"IR agency"}],"dollarAmounts":[{"amount":"£21.5 million","context":"Cash and cash equivalents as of March 31, 2026"},{"amount":"£24.3 million","context":"Cash and cash equivalents as of December 31, 2025"},{"amount":"£3.9 million","context":"Net loss for Q1 2026"},{"amount":"£2.5 million","context":"Net loss for Q1 2025"},{"amount":"£1.9 million","context":"Non-cash share-based payment expenses Q1 2026"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-14T20:02:36.884Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_earnings_plus_ind_clearance","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":28300,"modelName":"george-droid-qwen-72b"}}